benfluorex has been researched along with Diabetes Mellitus in 10 studies
Diabetes Mellitus: A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "3 ng/mL, means +/- SE), the clinical and metabolic effects of benfluorex (B), a lipid-lowering drug able to improve insulin sensitivity." | 9.08 | Benfluorex in obese noninsulin dependent diabetes mellitus patients poorly controlled by insulin: a double blind study versus placebo. ( Camisasca, R; Cassisa, C; Pacchioni, M; Piatti, PM; Pontiroli, AE; Pozza, G, 1996) |
| "To evaluate the change in lipids and insulin sensitivity in 10 obese type II diabetic patients after treatment with benfluorex or placebo for 2 wk." | 9.07 | Effects of benfluorex on insulin resistance and lipid metabolism in obese type II diabetic patients. ( Bianchi, R; Bongers, V; Bravenboer, B; Erkelens, DW, 1993) |
| "Benfluorex was withdrawn from European markets in June 2010 after reports of an association with heart valve lesions." | 5.38 | Increased risk of left heart valve regurgitation associated with benfluorex use in patients with diabetes mellitus: a multicenter study. ( Arnalsteen, E; Boulanger, J; Donal, E; Ederhy, S; Ennezat, PV; Garban, T; Jeu, A; Jobic, Y; Maréchaux, S; Réant, P; Rusinaru, D; Tribouilloy, C, 2012) |
| "Adjusted RR for mitral insufficiency and aortic insufficiency admissions were 2." | 5.36 | Benfluorex and valvular heart disease: a cohort study of a million people with diabetes mellitus. ( Allemand, H; Fagot, JP; Montastruc, JL; Neumann, A; Païta, M; Ricordeau, P; Simon, D; Tuppin, P; Weill, A, 2010) |
| "3 ng/mL, means +/- SE), the clinical and metabolic effects of benfluorex (B), a lipid-lowering drug able to improve insulin sensitivity." | 5.08 | Benfluorex in obese noninsulin dependent diabetes mellitus patients poorly controlled by insulin: a double blind study versus placebo. ( Camisasca, R; Cassisa, C; Pacchioni, M; Piatti, PM; Pontiroli, AE; Pozza, G, 1996) |
| "To evaluate the change in lipids and insulin sensitivity in 10 obese type II diabetic patients after treatment with benfluorex or placebo for 2 wk." | 5.07 | Effects of benfluorex on insulin resistance and lipid metabolism in obese type II diabetic patients. ( Bianchi, R; Bongers, V; Bravenboer, B; Erkelens, DW, 1993) |
| " As a derivative of fenfluramine with an appetite suppressant action, benfluorex is preferentially used in overweight patients." | 3.75 | Fenfluramine-like cardiovascular side-effects of benfluorex. ( Boutet, K; Carlhant-Kowalski, D; Frachon, I; Gut-Gobert, C; Humbert, M; Jobic, Y; Leroyer, C; Simonneau, G; Sitbon, O, 2009) |
| "Benfluorex + insulin is a valid alternative for obese patients who remain poorly controlled despite insulin or who require high doses of insulin." | 2.69 | Added benfluorex in obese insulin-requiring type 2 diabetes. ( Bauduceau, B; Brun, JM; Guillon-Metz, F; Leutenegger, M; Martin, C; Nicolino-Peltier, C; Richard, JL; Vannereau, D, 1998) |
| "Benfluorex hydrochloride has known lipid- and glucose-lowering effects." | 2.67 | Benfluorex decreases insulin resistance and improves lipid profiles in obese type 2 diabetic patients. ( Bianchi, R; Bongers, V; Bravenboer, B; Erkelens, DW, 1993) |
| "Benfluorex was withdrawn from European markets in June 2010 after reports of an association with heart valve lesions." | 1.38 | Increased risk of left heart valve regurgitation associated with benfluorex use in patients with diabetes mellitus: a multicenter study. ( Arnalsteen, E; Boulanger, J; Donal, E; Ederhy, S; Ennezat, PV; Garban, T; Jeu, A; Jobic, Y; Maréchaux, S; Réant, P; Rusinaru, D; Tribouilloy, C, 2012) |
| "Adjusted RR for mitral insufficiency and aortic insufficiency admissions were 2." | 1.36 | Benfluorex and valvular heart disease: a cohort study of a million people with diabetes mellitus. ( Allemand, H; Fagot, JP; Montastruc, JL; Neumann, A; Païta, M; Ricordeau, P; Simon, D; Tuppin, P; Weill, A, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (50.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tribouilloy, C | 3 |
| Maréchaux, S | 2 |
| Jobic, Y | 3 |
| Jeu, A | 2 |
| Ederhy, S | 2 |
| Donal, E | 2 |
| Réant, P | 2 |
| Arnalsteen, E | 2 |
| Boulanger, J | 2 |
| Garban, T | 2 |
| Ennezat, PV | 2 |
| Andréjak, M | 2 |
| Rusinaru, D | 3 |
| Boutet, K | 1 |
| Frachon, I | 1 |
| Gut-Gobert, C | 1 |
| Leroyer, C | 1 |
| Carlhant-Kowalski, D | 1 |
| Sitbon, O | 1 |
| Simonneau, G | 1 |
| Humbert, M | 1 |
| Henon, P | 1 |
| Tribouilloy, L | 1 |
| Leleu, F | 1 |
| Sevestre, H | 1 |
| Peltier, M | 1 |
| Caus, T | 1 |
| Weill, A | 1 |
| Païta, M | 1 |
| Tuppin, P | 1 |
| Fagot, JP | 1 |
| Neumann, A | 1 |
| Simon, D | 1 |
| Ricordeau, P | 1 |
| Montastruc, JL | 1 |
| Allemand, H | 1 |
| Bianchi, R | 2 |
| Bongers, V | 2 |
| Bravenboer, B | 2 |
| Erkelens, DW | 2 |
| Brindley, DN | 1 |
| Pontiroli, AE | 1 |
| Pacchioni, M | 1 |
| Piatti, PM | 1 |
| Cassisa, C | 1 |
| Camisasca, R | 1 |
| Pozza, G | 1 |
| Leutenegger, M | 1 |
| Bauduceau, B | 1 |
| Brun, JM | 1 |
| Guillon-Metz, F | 1 |
| Martin, C | 1 |
| Nicolino-Peltier, C | 1 |
| Richard, JL | 1 |
| Vannereau, D | 1 |
1 review available for benfluorex and Diabetes Mellitus
| Article | Year |
|---|---|
Mechanisms for the effects of benfluorex on the obese-diabetic-dyslipidemic syndrome.
Topics: Animals; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fenfluramine; Humans; Hyperlipidemias; Hypogl | 1993 |
4 trials available for benfluorex and Diabetes Mellitus
| Article | Year |
|---|---|
Benfluorex decreases insulin resistance and improves lipid profiles in obese type 2 diabetic patients.
Topics: Adult; Blood Glucose; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; | 1993 |
Effects of benfluorex on insulin resistance and lipid metabolism in obese type II diabetic patients.
Topics: Apolipoprotein A-I; Apolipoproteins B; Appetite Depressants; Blood Glucose; C-Peptide; Cholesterol; | 1993 |
Benfluorex in obese noninsulin dependent diabetes mellitus patients poorly controlled by insulin: a double blind study versus placebo.
Topics: 3-Hydroxybutyric Acid; Appetite Depressants; Body Weight; C-Peptide; Diabetes Mellitus; Diabetes Mel | 1996 |
Added benfluorex in obese insulin-requiring type 2 diabetes.
Topics: Adolescent; Adult; Aged; Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus; Diabetes Mellitus | 1998 |
5 other studies available for benfluorex and Diabetes Mellitus
| Article | Year |
|---|---|
Frequency of drug-induced valvular heart disease in patients previously exposd to benfluorex: a multicentre prospective study.
Topics: Analysis of Variance; Aortic Valve Insufficiency; Appetite Depressants; Case-Control Studies; Diabet | 2013 |
Fenfluramine-like cardiovascular side-effects of benfluorex.
Topics: Appetite Depressants; Cardiovascular Diseases; Diabetes Mellitus; Female; Fenfluramine; Heart Valve | 2009 |
Restrictive organic mitral regurgitation associated with benfluorex therapy.
Topics: Aged; Appetite Depressants; Body Mass Index; Cardiomyopathy, Restrictive; Diabetes Mellitus; Drug Th | 2010 |
Benfluorex and valvular heart disease: a cohort study of a million people with diabetes mellitus.
Topics: Adult; Aged; Aortic Valve Insufficiency; Appetite Depressants; Cohort Studies; Databases, Factual; D | 2010 |
Increased risk of left heart valve regurgitation associated with benfluorex use in patients with diabetes mellitus: a multicenter study.
Topics: Aged; Aortic Valve Insufficiency; Appetite Depressants; Diabetes Mellitus; Echocardiography; Europe; | 2012 |